• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

德瑞蒂斯比值在上尿路肿瘤肾输尿管切除术后膀胱复发预测生存中的预后价值

Prognostic Value of the De Ritis Ratio in Predicting Survival After Bladder Recurrence Following Nephroureterectomy for Upper Urinary Tract Tumors.

作者信息

Yorulmaz Enis Mert, Donmez Kursad, Ozcan Serkan, Kose Osman, Gorgel Sacit Nuri, Candemir Enes, Akin Yigit

机构信息

Department of Urology, Izmir Katip Celebi University, Izmir 35620, Turkey.

Department of Urology, Ataturk Research and Training Hospital, Izmir 35360, Turkey.

出版信息

Diagnostics (Basel). 2025 Jul 22;15(15):1840. doi: 10.3390/diagnostics15151840.

DOI:10.3390/diagnostics15151840
PMID:40804804
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12346446/
Abstract

: Upper tract urothelial carcinoma (UTUC) is often complicated by intravesical recurrence and cancer progression following radical nephroureterectomy (RNU). Identifying reliable prognostic biomarkers remains crucial for optimizing postoperative surveillance. The goal of this study was to assess the prognostic value of the De Ritis ratio (AST/ALT) in predicting bladder recurrence and oncologic outcomes in patients with clinically localized UTUC undergoing RNU. : This retrospective study analyzed 87 patients treated with RNU between 2018 and 2025. Preoperative De Ritis ratios were calculated, and an optimal cut-off value of 1.682 was determined using ROC analysis. Recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) were analyzed using the Kaplan-Meier and Cox regression methods. Logistic regression was used to identify independent predictors of bladder recurrence. : A high De Ritis ratio was significantly associated with increased bladder recurrence and worse RFS and CSS, but not OS. Multivariate analysis confirmed that an elevated De Ritis ratio, current smoking, positive surgical margins, and synchronous bladder cancer were the independent predictors of bladder recurrence. The De Ritis ratio demonstrated strong discriminatory performance (AUC: 0.807), with good sensitivity and specificity for predicting recurrence. : The De Ritis ratio is a simple, cost-effective preoperative biomarker that may aid in identifying UTUC patients at higher risk for intravesical recurrence and cancer-specific mortality. Incorporating this ratio into clinical decision-making could enhance risk stratification and guide tailored follow-up strategies.

摘要

上尿路尿路上皮癌(UTUC)在根治性肾输尿管切除术(RNU)后常并发膀胱内复发和癌症进展。识别可靠的预后生物标志物对于优化术后监测仍然至关重要。本研究的目的是评估德瑞蒂斯比值(AST/ALT)在预测接受RNU的临床局限性UTUC患者膀胱复发和肿瘤学结局方面的预后价值。

这项回顾性研究分析了2018年至2025年间接受RNU治疗的87例患者。计算术前德瑞蒂斯比值,并使用ROC分析确定最佳临界值为1.682。采用Kaplan-Meier法和Cox回归法分析无复发生存期(RFS)、癌症特异性生存期(CSS)和总生存期(OS)。采用逻辑回归确定膀胱复发的独立预测因素。

高德瑞蒂斯比值与膀胱复发增加、RFS和CSS较差显著相关,但与OS无关。多因素分析证实,德瑞蒂斯比值升高、当前吸烟、手术切缘阳性和同步性膀胱癌是膀胱复发的独立预测因素。德瑞蒂斯比值表现出较强的鉴别性能(AUC:0.807),对预测复发具有良好的敏感性和特异性。

德瑞蒂斯比值是一种简单、经济有效的术前生物标志物,可能有助于识别膀胱内复发和癌症特异性死亡风险较高的UTUC患者。将该比值纳入临床决策可以加强风险分层并指导个性化的随访策略。

相似文献

1
Prognostic Value of the De Ritis Ratio in Predicting Survival After Bladder Recurrence Following Nephroureterectomy for Upper Urinary Tract Tumors.德瑞蒂斯比值在上尿路肿瘤肾输尿管切除术后膀胱复发预测生存中的预后价值
Diagnostics (Basel). 2025 Jul 22;15(15):1840. doi: 10.3390/diagnostics15151840.
2
Impact of a novel immune and nutritional score on prognosis in patients with upper urinary tract urothelial carcinoma following radical nephroureterectomy.新型免疫和营养评分对根治性肾输尿管切除术治疗上尿路上皮癌患者预后的影响。
J Cancer Res Clin Oncol. 2023 Sep;149(12):10893-10909. doi: 10.1007/s00432-023-04977-8. Epub 2023 Jun 15.
3
Development and validation of a nomogram based on geriatric nutritional risk index for predicting prognosis and postoperative complications in surgical patients with upper urinary tract urothelial carcinoma.基于老年营养风险指数的列线图的开发和验证,用于预测上尿路尿路上皮癌手术患者的预后和术后并发症。
J Cancer Res Clin Oncol. 2023 Dec;149(20):18185-18200. doi: 10.1007/s00432-023-05462-y. Epub 2023 Nov 30.
4
Long-term impact of synchronous and metachronous bladder cancer on prognosis after radical nephroureterectomy for upper urinary tract urothelial carcinoma: results from a large population-based cohort in China.同步性和异时性膀胱癌对上尿路尿路上皮癌根治性肾输尿管切除术后预后的长期影响:来自中国一项基于大人群队列的研究结果
Int J Surg. 2025 Jul 3. doi: 10.1097/JS9.0000000000002892.
5
Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel.保留肾单位手术与根治性肾输尿管切除术治疗上尿路上皮癌的肿瘤学结局:EAU 非肌肉浸润性膀胱癌指南小组的系统评价。
Eur Urol. 2016 Dec;70(6):1052-1068. doi: 10.1016/j.eururo.2016.07.014. Epub 2016 Jul 28.
6
Oncological outcomes of open versus minimally invasive nephroureterectomy for locally advanced upper tract urothelial carcinoma.开放性与微创性肾输尿管切除术治疗局部晚期上尿路尿路上皮癌的肿瘤学结局
World J Urol. 2025 Jul 23;43(1):452. doi: 10.1007/s00345-025-05815-x.
7
Endoscopic intervention versus radical nephroureterectomy for the management of localized upper urinary tract urothelial carcinoma: a systematic review and meta-analysis of comparative studies.内镜介入与根治性肾输尿管切除术治疗局限性上尿路上皮癌的比较:系统评价和荟萃分析。
World J Urol. 2024 May 14;42(1):318. doi: 10.1007/s00345-024-05032-y.
8
A Systematic Review and Meta-analysis of Clinicopathologic Factors Linked to Intravesical Recurrence After Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma.根治性肾输尿管切除术治疗上尿路上皮癌后膀胱内复发的临床病理因素的系统评价和荟萃分析。
Eur Urol. 2015 Jun;67(6):1122-1133. doi: 10.1016/j.eururo.2014.11.035. Epub 2014 Dec 6.
9
External validation of current quality care metrics after radical nephroureterectomy.根治性肾输尿管切除术后当前质量护理指标的外部验证
BJU Int. 2025 Aug;136(2):261-270. doi: 10.1111/bju.16741. Epub 2025 Apr 20.
10
Development and external validation of a novel nomogram to predict intravesical recurrence after radical nephroureterectomy: a multicenter study.开发并验证一种新的列线图预测根治性肾输尿管切除术术后膀胱内复发:一项多中心研究。
J Cancer Res Clin Oncol. 2023 Oct;149(13):11223-11231. doi: 10.1007/s00432-023-05016-2. Epub 2023 Jun 24.

本文引用的文献

1
The role of intravesical chemotherapy following nephroureterectomy in upper tract urothelial carcinoma: A systematic review and meta-analysis.肾输尿管切除术治疗上尿路尿路上皮癌后膀胱内化疗的作用:一项系统评价和荟萃分析。
Urol Oncol. 2025 Mar;43(3):191.e1-191.e12. doi: 10.1016/j.urolonc.2024.10.035. Epub 2024 Nov 25.
2
Single Early Intravesical Instillation of Epirubicin for Preventing Bladder Recurrence after Nephroureterectomy in Upper Urinary Tract Urothelial Carcinoma.表柔比星单次早期膀胱内灌注预防上尿路尿路上皮癌肾输尿管切除术后膀胱复发
Cancer Res Treat. 2024 Jul;56(3):877-884. doi: 10.4143/crt.2023.1219. Epub 2024 Jan 17.
3
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.
欧洲泌尿外科学会上尿路尿路上皮癌指南:2023 年更新版。
Eur Urol. 2023 Jul;84(1):49-64. doi: 10.1016/j.eururo.2023.03.013. Epub 2023 Mar 24.
4
A Retrospective Analysis of the De Ritis Ratio in Muscle Invasive Bladder Cancer, with Focus on Tumor Response and Long-Term Survival in Patients Receiving Neoadjuvant Chemotherapy and in Chemo Naïve Cystectomy Patients-A Study of a Clinical Multicentre Database.肌肉浸润性膀胱癌中德瑞蒂斯比值的回顾性分析,重点关注接受新辅助化疗患者和初治膀胱切除术患者的肿瘤反应及长期生存——一项临床多中心数据库研究
J Pers Med. 2022 Oct 27;12(11):1769. doi: 10.3390/jpm12111769.
5
Oncologic Surveillance After Radical Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma.高危上尿路尿路上皮癌根治性肾输尿管切除术的肿瘤学监测。
Eur Urol Oncol. 2022 Aug;5(4):451-459. doi: 10.1016/j.euo.2022.04.003. Epub 2022 May 2.
6
Association Between Preoperative De Ritis (AST/ALT) Ratio and Oncological Outcomes Following Radical Cystectomy in Patients With Urothelial Bladder Cancer.术前 De Ritis(AST/ALT)比值与膀胱癌患者根治性膀胱切除术后肿瘤学结局的关系。
Clin Genitourin Cancer. 2022 Apr;20(2):e89-e93. doi: 10.1016/j.clgc.2021.10.007. Epub 2021 Oct 25.
7
Prognostic Role of Pretreatment De Ritis Ratio (Aspartate Transaminase/Alanine Transaminase Ratio) in Urological Cancers: A Systematic Review and Meta-Analysis.治疗前德瑞蒂斯比值(天冬氨酸转氨酶/丙氨酸转氨酶比值)在泌尿系统癌症中的预后作用:一项系统评价和荟萃分析
Front Oncol. 2020 Sep 4;10:1650. doi: 10.3389/fonc.2020.01650. eCollection 2020.
8
Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy.术前 De Ritis 比值在上尿路尿路上皮癌行肾输尿管切除术治疗中的预后作用。
Urol Oncol. 2020 Jun;38(6):601.e17-601.e24. doi: 10.1016/j.urolonc.2020.02.008. Epub 2020 Feb 29.
9
De Ritis Ratio (Aspartate Transaminase/Alanine Transaminase) as a Significant Prognostic Factor in Patients Undergoing Radical Cystectomy with Bladder Urothelial Carcinoma: A Propensity Score-Matched Study.De Ritis 比值(天冬氨酸氨基转移酶/丙氨酸氨基转移酶)作为接受根治性膀胱切除术的膀胱癌患者的重要预后因素:一项倾向评分匹配研究。
Dis Markers. 2019 Aug 27;2019:6702964. doi: 10.1155/2019/6702964. eCollection 2019.
10
Prognostic value of aspartate transaminase to alanine transaminase (De Ritis) ratio in solid tumors: a pooled analysis of 9,400 patients.天冬氨酸转氨酶与丙氨酸转氨酶(德瑞蒂斯)比值在实体瘤中的预后价值:9400例患者的汇总分析
Onco Targets Ther. 2019 Jul 2;12:5201-5213. doi: 10.2147/OTT.S204403. eCollection 2019.